万春医药上涨5.07%，报2.154美元/股，总市值8683.73万美元

Group 1 - The stock price of BeyondSpring Inc. (BYSI) increased by 5.07% on August 6, reaching $2.154 per share, with a total market capitalization of $86.8373 million [1] - As of June 30, 2024, BeyondSpring reported total revenue of $1.0 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a year-over-year increase of 42.91% [1] Group 2 - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, with a novel, scalable business model aimed at efficient and low-cost drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]